Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1635034 | 0.90 | PTGS2 (0.47) | PTGS2MAPTMEN1KMT2ATP53 | |
| SCHEMBL1636061 | 0.88 | ACHE (0.46) | PTGS2MAPTMEN1KMT2AABCG2 | |
| SCHEMBL1634097 | 0.87 | PTGS2 (0.48) | PTGS2MAPTMEN1KMT2ATP53 | |
| SCHEMBL1634812 | 0.82 | PTGS2 (0.48) | PTGS2PTGS1MAPTMEN1KMT2A | |
| SCHEMBL1634814 | 0.82 | PTGS2 (0.48) | PTGS2PTGS1MAPTMEN1KMT2A | |
| SCHEMBL1635088 | 0.81 | ALDH1A1 (0.38) | MAPTMEN1KMT2AABCG2KDM4E | |
| SCHEMBL1635153 | 0.78 | PTGS2 (0.52) | PTGS2PTGS1MAPTMEN1KMT2A | |
| SCHEMBL1635156 | 0.78 | PTGS2 (0.52) | PTGS2PTGS1MAPTMEN1KMT2A | |
| SCHEMBL1634811 | 0.76 | TRPV1 (0.62) | PTGS2MAPTMEN1KMT2ATP53 | |
| SCHEMBL1634809 | 0.76 | TRPV1 (0.62) | PTGS2MAPTMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | US | claimed |
| EP-3138832-A1 | SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS | Temple University - Of The Commonwealth System of Higher Education (US) | 2017-03-08 | — | — | EP | disclosed |
| US-7932242-B2 | Anticancer agents; radiation and chemical resistance | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | PCNA, MKI67, TP53 | PTGS2 439/4885PTGS1 199/4885MAPT 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.